Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1BEZAFIBRATE
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
2Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94 💬
3Bezafibrate (drug)
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 316 💬
4Bezafibrate (INN 3968)
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 324 💬
5Bezafibrate 100 mg
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
6Bezafibrate 200 MG
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
7Bezafibrate 200 mg in addition to UDCA therapy
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
8Bezafibrate 200 MG Oral Tablet
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
9Bezafibrate 400 MG
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
10Bezafibrate 400 mg in addition to UDCA therapy
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
11Bezafibrate IR
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
12Bezafibrate SR
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
13Bezafibrate, Beza, BZF, Bezalip
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
14Bezafibrate, Beza, BZF, Bezalip mono
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: PPARA 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬